Piezo Therapeutics, Inc.
Piezo Therapeutics is a company focused on addressing the key problem of nucleic acid medicine delivery. They leverage proprietary energy-driven platforms, specifically Piezopen, to enable safe, simple, and scalable delivery of RNA and DNA medicines. Their mission is to improve the efficacy, safety, affordability, and scalability of nucleic acid therapeutics across various disease areas, including infectious diseases, immuno-oncology, chronic diseases, and dermatology. They actively support partners from startups to established pharmaceutical companies, aiming to transform the landscape of genetic medicines.
Industries
Nr. of Employees
small (1-50)
Piezo Therapeutics, Inc.
Products
Piezoelectric microneedle electroporator (pen-like device)
A compact electroporation device combining a piezoelectric pulse generator with a microneedle electrode array to enable localized, formulation-free intracellular delivery of nucleic acids.
Piezoelectric microneedle electroporator (pen-like device)
A compact electroporation device combining a piezoelectric pulse generator with a microneedle electrode array to enable localized, formulation-free intracellular delivery of nucleic acids.
Services
Collaborative partnerships to integrate a formulation-free electroporation delivery platform with external nucleic acid payloads and development programs.
Services spanning vector selection, construct optimization, preclinical validation across species, and regulatory strategy to support clinical translation.
Advisory and partnership services for scalable manufacturing approaches, including rapid deployment strategies for large-scale and point-of-care production without formulation requirements.
Collaborative partnerships to integrate a formulation-free electroporation delivery platform with external nucleic acid payloads and development programs.
Services spanning vector selection, construct optimization, preclinical validation across species, and regulatory strategy to support clinical translation.
Advisory and partnership services for scalable manufacturing approaches, including rapid deployment strategies for large-scale and point-of-care production without formulation requirements.
Expertise Areas
- Nucleic acid delivery platform development
- Electroporation and microneedle engineering
- Vaccine delivery and immunogenicity
- Dermal gene therapy
Key Technologies
- Piezoelectric pulse generation for electroporation
- Microneedle electrode arrays
- Electroporation-based intracellular delivery
- mRNA / self-amplifying RNA / circular RNA delivery
News & Updates
World-renowned experts across infectious diseases, vaccines, and dermatology to advise Piezo on advancing its energy-based delivery platform and internal programs to the clinic
Publication describes a new delivery platform (Piezopen) that augments gene expression and immunogenicity to a "naked" mRNA vaccine comparable to benchmark LNP formulations. It delivers diverse cargos and across species, with potential to improve dosing, reactogenicity, durability, cost, and manufacturing hurdles of mRNA vaccines by eliminating LNPs.
Piezo is developing a simple, affordable, and scalable platform designed for rapid, safe, and efficient delivery of nucleic acid medicines, including RNA/DNA vaccines, therapeutic proteins, and dermal gene therapies. It was invented by Georgia Tech researchers and launched with $2 million in seed funding from Open Philanthropy.
World-renowned experts across infectious diseases, vaccines, and dermatology to advise Piezo on advancing its energy-based delivery platform and internal programs to the clinic
Publication describes a new delivery platform (Piezopen) that augments gene expression and immunogenicity to a "naked" mRNA vaccine comparable to benchmark LNP formulations. It delivers diverse cargos and across species, with potential to improve dosing, reactogenicity, durability, cost, and manufacturing hurdles of mRNA vaccines by eliminating LNPs.
Piezo is developing a simple, affordable, and scalable platform designed for rapid, safe, and efficient delivery of nucleic acid medicines, including RNA/DNA vaccines, therapeutic proteins, and dermal gene therapies. It was invented by Georgia Tech researchers and launched with $2 million in seed funding from Open Philanthropy.